Sequential Skin: Revolutionising atopic dermatitis diagnosis through a novel skin microbiome test.

连续皮肤：通过新型皮肤微生物组测试彻底改变特应性皮炎的诊断。

• 批准号: 10034778
• 金额: $ 35.53万
• 依托单位: SEQUENTIAL SKIN LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10034778
• 关键词: Sequential; Skin; Revolutionising; atopic; dermatitis

Atopic dermatitis (AD) is a multifactorial chronic and recurrent inflammatory skin disease, affecting 1-in-5 UK children and 1-in-10 adults. Circa.29% are moderate/severe cases -- affecting over 1.97million patients in the UK alone -- with healthcare and socio-economic costs exceeding £723million annually.With no definitive cure, a significant therapeutic challenge to manage AD flare-ups/progression arises from:* Complexity across varied AD conditions/pathogeneses* Many disparate patient populations* Over 1000 potential therapeutic pathways across different treatments and formulationsHowever, capability of incumbent diagnostic approaches to effectively inform/target these existing treatments is limited.Furthermore, whilst recent research demonstrates that patients' skin microbiome can dictate disease progression, no practical clinical tool for precision skin microbiome analysis exists, preventing patient stratification for emerging personalised AD medicines/treatments.Consequently, treatment pathways (NHS/private) are trial-and-error over multiple visits, failing to adequately:* Relieve symptoms* Minimise side effects* Mitigate disease progression.Sequential Skin Ltd have already introduced a disruptive consumer skin-test for cosmetic skin health applications, based on proprietary:* Analysis of key bacterial microbiome-markers, alongside genetic sequencing* Patches for non-invasive skin sampling, already achieving significantly higher collection efficiency than existing swabs and tape-stripping gold-standards* Laboratory processes reducing time-around for skin molecular results by 75% with respect to other direct-to-consumer genetic testing companiesLeveraging breakthrough research demonstrating improved prediction of AD progression using microbial DNA biomarker clusters, Sequential Skin now aim to extend these developments into the clinical domain, targeting the first non-invasive clinical bioinformatic solution for patient-specific AD profiling and treatment prognosis.

特应性皮炎（AD）是一种多因素慢性和复发性炎症性皮肤病，影响1/5的英国儿童和1/10的成人。大约29%是中度/重度病例-仅在英国就影响超过197万患者-每年的医疗保健和社会经济成本超过7.23亿英镑。由于没有明确的治愈方法，管理AD发作/进展的重大治疗挑战来自：* 各种AD病症/病因的复杂性 * 许多不同的患者群体 * 不同治疗和制剂的1000多种潜在治疗途径然而，此外，虽然最近的研究表明患者的皮肤微生物组可以决定疾病的进展，但不存在用于精确皮肤微生物组分析的实用临床工具，防止患者对新兴的个性化AD药物/治疗进行分层。因此，（NHS/私人）是试错多次访问，未能充分：* 缓解症状 * 最大限度地减少副作用 * 缓解疾病进展.连续皮肤有限公司已经推出了一个破坏性的消费者皮肤测试化妆品皮肤健康应用，基于专有：* 分析关键的细菌微生物组标记，以及基因测序 * 用于非侵入性皮肤采样的贴片，与现有的拭子和胶带剥离金标准相比，已经实现了显著更高的收集效率 * 实验室流程将皮肤分子结果的时间缩短了75%，利用突破性研究证明使用微生物DNA生物标志物簇可以改善AD进展的预测，Sequential Skin现在的目标是将这些发展扩展到临床领域，目标是第一个用于患者特定AD分析和治疗预后的非侵入性临床生物信息学解决方案。